8 completed, 4 recruiting, 3 withdrawn, 2 active not recruiting. 13 Phase 2, 6 Phase 1, 3 Phase 3, 1 Early Phase 1, 1 Not applicable.
Follow Rabbit anti-thymocyte globulin: new trials by email Literature Review of Rabbit anti-thymocyte globulin trials Research Report on Rabbit anti-thymocyte globulin
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study Comparing Siplizumab With Rabbit Anti-Thymocyte Globulin to Help the Body Accept a Kidney Transplant Siplizumab, Rabbit anti-thymocyte globulin - Renal Transplant Failure and Rejection | Phase 2 | Recruiting | Nefro Avillion Clinical Development, LLC | 120 | 2026-06-29 | 2026-10-06 |
| A Study to Investigate the Efficacy and Safety of Frexalimab Versus Tacrolimus in Adults Undergoing Kidney Transplantation Frexalimab, Tacrolimus, rabbit anti-thymocyte globulin - Kidney Transplant Rejection | Phase 2 / Phase 3 | Recruiting | Sanofi | 526 | 2026-03-13 | 2026-10-13 |
| Mismatched Related Donor Versus Matched Unrelated Donor Stem Cell Transplantation for Children, Adolescents, and Young Adults With Acute Leukemia or Myelodysplastic Syndrome Biospecimen Collection, Bone Marrow Aspiration, Busulfan - Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia | Phase 3 | Active not recruiting | Children's Oncology Group | 66 | 2023-03-15 | 2026-07-30 |
| Treosulfan-Based Conditioning Regimen Before a Blood or Bone Marrow Transplant for the Treatment of Bone Marrow Failure Diseases (BMT CTN 1904) Treosulfan, Fludarabine Phosphate, Tacrolimus - Bone Marrow Failure Syndrome, Congenital Amegakaryocytic Thrombocytopenia | Phase 2 | Completed | Fred Hutchinson Cancer Center | 40 | 2022-04-19 | 2026-03-09 |
| Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Thiotepa in Treating Patients With Non-malignant Disorders Thiotepa, Treosulfan, Fludarabine Phosphate - Non-Neoplastic Hematopoietic and Lymphoid Cell Disorder | Phase 2 | Recruiting | Fred Hutchinson Cancer Center | 40 | 2021-05-05 | 2026-09-16 |
| Chemotherapy and Donor Stem Transplant for the Treatment of Patients With High Grade Brain Cancer Etoposide, Fludarabine Phosphate, Hematopoietic Cell Transplantation - Anaplastic Ependymoma, Atypical Teratoid/Rhabdoid Tumor | Phase 1 | Withdrawn | M.D. Anderson Cancer Center | 2021-01-14 | 2024-10-26 | |
| Pre-transplant Immunosuppression and Donor Stem Cell Transplant for the Treatment of Severe Hemoglobinopathies Bortezomib, Busulfan, Cyclophosphamide - Beta Thalassemia Major, Sickle Beta 0 Thalassemia | Early Phase 1 | Withdrawn | M.D. Anderson Cancer Center | 2020-12-29 | 2024-10-24 | |
| Donor Stem Cell Transplant After Chemotherapy for the Treatment of Recurrent or Refractory High-Risk Solid Tumors in Pediatric and Adolescent-Young Adults Allogeneic Hematopoietic Stem Cell Transplantation, Cyclosporine, Etoposide - Desmoplastic Small Round Cell Tumor, Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor | Phase 2 | Terminated | M.D. Anderson Cancer Center | 1 | 2020-08-19 | 2025-06-29 |
| Total Body Irradiation and Astatine-211-Labeled BC8-B10 Monoclonal Antibody for the Treatment of Nonmalignant Diseases Astatine At 211 Anti-CD45 Monoclonal Antibody BC8-B10, Fludarabine, Cyclophosphamide - Non-Malignant Neoplasm | Phase 1 / Phase 2 | Recruiting | Fred Hutchinson Cancer Center | 40 | 2020-06-16 | 2026-06-17 |
| Antithymocyte Globulin as a Second Line Therapy in Graves Orbitopathy rabbit anti-thymocyte globulin - Graves Orbitopathy | Not applicable | Unknown | Medical University of Silesia | 20 | 2020-01-01 | 2022-01-20 |
| Transplantation for Patients With Sickle Cell Disease From Mismatched Family Donors of Bone Marrow Bone Marrow Transplant (BMT), Hydroxyurea, Thiotepa - Sickle Cell Disease | Phase 2 | Completed | Emory University | 10 | 2019-07-10 | 2023-10-12 |
| A Blood Stem Cell Transplant for Sickle Cell Disease Cyclophosphamide, Pentostatin, Rabbit anti-thymocyte globulin - Sickle Cell Disease, Sickle Cell Disorder | Phase 1 | Active not recruiting | City of Hope Medical Center | 3 | 2019-01-04 | 2026-03-05 |
| Study To Examine Toxicity Of Allogeneic Stem Cell Transplantation For Relapsed Or Therapy Refractory Ewings Sarcoma Rabbit anti-thymocyte globulin, Busulfan, Melphalan - EWINGS SARCOMA | Phase 1 | Completed | University of Louisville | 10 | 2013-04-01 | 2017-05-09 |
| Nonmyeloablative Stem Cell Transplantation for Chronic Lymphocytic Leukemia (CLL) Lenalidomide, Fludarabine, Rituximab - Chronic Lymphocytic Leukemia | Phase 2 | Terminated | M.D. Anderson Cancer Center | 39 | 2009-05-06 | 2020-01-27 |
| Phase 2 Study of Autologous Followed by Nonmyeloablative Allogeneic Transplantation Using TLI & ATG Autologous peripheral blood stem cells (auto-PBSC) transplantation, Allogeneic peripheral blood stem cells (allo-PBSC) transplantation, Filgrastim - Transplantation, Homologous, Transplantation, Autologous | Phase 2 | Completed | Stanford University | 9 | 2009-05-01 | 2017-10-20 |
| Phase I/II Thymus Transplantation With Immunosuppression #950 Cultured Thymus Tissue for Implantation (CTTI), Cultured Thymus Tissue Implantation and Parental Parathyroid Transplantation, Blood Draw - DiGeorge Anomaly, Complete DiGeorge Anomaly | Phase 1 / Phase 2 | Completed | Sumitomo Pharma Switzerland GmbH | 14 | 2005-12-19 | 2022-03-25 |
| Lupus Immunosuppressive/Immunomodulatory Therapy or Stem Cell Transplant (LIST) Leukapheresis, Non-myeloablative high dose immunosuppressive therapy conditioning (HDIT), Autologous CD34+HPC transplantation (HSCT) - Systemic Lupus Erythematosus | Phase 2 | Withdrawn | National Institute of Allergy and Infectious Diseases (NIAID) | 2005-09-01 | 2013-02-01 | |
| Safety/Efficacy of Induction Agents With Tacrolimus, MMF, and Rapid Steroid Withdrawal in Renal Transplant Recipients basiliximab, rabbit anti-thymocyte globulin, tacrolimus - Kidney Transplantation | Phase 4 | Completed | Astellas Pharma Inc | 501 | 2005-05-01 | 2011-08-11 |
| Risk-Adapted Allogeneic Stem Cell Transplantation For Mixed Donor Chimerism In Patients With Non-Malignant Diseases Fludarabine, Cyclophosphamide, Busulfan - Bone Marrow Failure, Osteopetrosis | Phase 2 / Phase 3 | Completed | Columbia University | 38 | 2002-09-01 | 2024-10-31 |
| Allo Transplantation With Mylotarg, Fludarabine and Melphalan for AML, CML and MDS Mylotarg, Fludarabine, Melphalan - Acute Myelogenous Leukemia, Myelodysplastic Syndrome | Phase 1 / Phase 2 | Completed | M.D. Anderson Cancer Center | 47 | 2001-05-01 | 2012-08-01 |
Anemia, Sickle Cell (3) · Bone Marrow Failure Disorders (2) · Leukemia, Lymphocytic, Chronic, B-Cell (2) · Leukemia, Myeloid, Acute (2) · Myelodysplastic Syndromes (2) · Anemia, Diamond-Blackfan (1) · Anemia, Hypochromic (1) · Brain Neoplasms (1) · Choroid Plexus Carcinoma (1) · Congenital amegakaryocytic thrombocytopenia (1) · Desmoplastic Small Round Cell Tumor (1) · DiGeorge Syndrome (1) · Ependymoma (1) · Exophthalmos (1) · Fanconi Anemia (1)
M.D. Anderson Cancer Center (5) · Fred Hutchinson Cancer Center (3) · Astellas Pharma Inc (1) · Children's Oncology Group (1) · City of Hope Medical Center (1) · Columbia University (1) · Emory University (1) · Medical University of Silesia (1) · National Institute of Allergy and Infectious Diseases (NIAID) (1) · Nefro Avillion Clinical Development, LLC (1) · Sanofi (1) · Stanford University (1) · Sumitomo Pharma Switzerland GmbH (1) · University of Louisville (1)
United States (17) · Australia (2) · Brazil (2) · Spain (2) · Argentina (1) · Belgium (1) · Canada (1) · Chile (1) · China (1) · Czechia (1) · Denmark (1) · Finland (1) · France (1) · Hungary (1) · Israel (1)
Ann Traynor, MD (1) · Betty Diamond, MD (1) · Bevra Hahn, MD (1) · Heather J Symons (1) · Issa F. Khouri, MD, BS (1) · James Garvin, MD, PhD (1) · Jeremy S Connors, MD (1) · Jerzy Chudek, Prof. (1) · Joseph Rosenthal, MD (1) · Keith Sullivan, MD (1) · Kenneth Kalunian, MD (1) · Kenneth Lucas, M.D. (1) · Kris M Mahadeo (1) · Kris M Mahadeo, MD (1)
PMID 18035553, PMID 18424759, PMID 18557726, PMID 19066739, PMID 20236866, PMID 23607606, PMID 35615718
2025 (1), K12HD043494 (1), P01HL122173 (1), R01AI047040 (1), R01AI054843 (1), U10CA180886 (1), U10HL069294 (1)